Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple‐negative breast cancer, adversely affects survival

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Histopathology

• Publication date

  2016-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/his.12801PMID 26259780
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer

  2014cited by this paper
• miR-342 Regulates BRCA1 Expression through Modulation of ID4 in Breast Cancer

  2014cited by this paper
• Id4 dependent acetylation restores mutant-p53 transcriptional activity

  2013cited by this paper
• Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort

  2013cited by this paper
• p53 mutations in cancer

  2013cited by this paper
• Roles of p53 and p16 in triple-negative breast cancer

  2013cited by this paper
• Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer

  2013cited by this paper
• Methylation of BRCA1 Promoter Region Is Associated with Unfavorable Prognosis in Women with Early-Stage Breast Cancer

  2013cited by this paper
• Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines

  2013cited by this paper
• Triple-negative breast cancer and PTEN (phosphatase and tensin homologue)loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer

  2012cited by this paper
• Cooperativity of Rb, Brca1, and p53 in Malignant Breast Cancer Evolution

  2012cited by this paper
• BRCA2 Mutations and Triple-Negative Breast Cancer

  2012cited by this paper
• Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation

  2012influential reference
• Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.

  2011cited by this paper
• Inhibitor of DNA-binding 4 contributes to the maintenance and expansion of cancer stem cells in 4T1 mouse mammary cancer cell line

  2011cited by this paper
• p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features.

  2011cited by this paper
• ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2.

  2011cited by this paper
• Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women

  2011cited by this paper
• American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer

  2010cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• ID4: a new player in the cancer arena

  2010cited by this paper
• Triple Negative Breast Cancer: Outcome Correlation With Immunohistochemical Detection of Basal Markers

  2010cited by this paper
• The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis

  2009cited by this paper
• Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer

  2008cited by this paper
• BRCA1 regulates human mammary stem/progenitor cell fate

  2008cited by this paper
• BRCA1 dysfunction in sporadic basal-like breast cancer

  2007cited by this paper
• BRCA1 and BRCA2 Mutations in an Asian Clinic-based Population Detected Using a Comprehensive Strategy

  2007cited by this paper
• Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.

  2007cited by this paper
• The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

  2007cited by this paper
• Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.

  2006cited by this paper
• Basal-like breast cancer and the BRCA1 phenotype

  2006cited by this paper
• Tumoral expression of BRCA1, Estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer

  2006cited by this paper
• Id family of helix-loop-helix proteins in cancer

  2005cited by this paper
• BRCA1 Gene Expression in Breast Cancer: A Correlative Study between Real-time RT-PCR and Immunohistochemistry

  2005cited by this paper
• Molecular classification and molecular forecasting of breast cancer: ready for clinical application?

  2005cited by this paper
• Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype

  2005cited by this paper
• Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia

  2005cited by this paper
• BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles

  2005cited by this paper
• Id family of helix-loop-helix proteins in cancer

  2005cited by this paper
• Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer

  2005cited by this paper
• Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

  2004cited by this paper
• Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

  2004cited by this paper
• Epigenetic Inactivation of ID4 in Colorectal Carcinomas Correlates with Poor Differentiation and Unfavorable Prognosis

  2004cited by this paper
• The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives

  2003cited by this paper
• Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma

  2003cited by this paper
• Helix-Loop-Helix Proteins in Mammary Gland Development and Breast Cancer

  2003cited by this paper
• The p53 pathway in breast cancer

  2002cited by this paper
• The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study

  2001cited by this paper
• IMMUNOHISTOCHEMICAL EXPRESSION OF HORMONE RECEPTORS IN INVASIVE BREAST CARCINOMA: CORRELATION OF RESULTS OF H‐SCORE WITH PATHOLOGICAL PARAMETERS

  2001cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• The Id proteins and angiogenesis

  2001cited by this paper
• Regulation of Pax3 transcriptional activity by SUMO-1-modified PML

  2001cited by this paper
• Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis

  2001cited by this paper
• Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach.

  2001influential reference
• The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives

  2000cited by this paper
• Tumor Suppressor p53 Is Required To Modulate BRCA1 Expression

  2000cited by this paper
• Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.

  2000cited by this paper
• BRCA1, BRCA2 and their possible function in DNA damage response

  1999cited by this paper
• Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.

  1999cited by this paper
• Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas

  1999cited by this paper
• Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.

  1999cited by this paper
• Overexpression of BRCA2 gene in sporadic breast tumours

  1999cited by this paper
• Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

  1998cited by this paper
• Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells

  1998cited by this paper
• BRCA1 required for transcription-coupled repair of oxidative DNA damage.

  1998cited by this paper
• Each member of the Id gene family exhibits a unique expression pattern in mouse gastrulation and neurogenesis

  1997cited by this paper
• Induction of apoptosis by the tumor suppressor protein BRCA1.

  1996cited by this paper
• The expression pattern of Id4, a novel dominant negative helix-loop-helix protein, is distinct from Id1, Id2 and Id3.

  1994cited by this paper
• Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome

  year unknowncited by this paper

• Exploring ID4 as a driver of aggression and a therapeutic target in triple-negative breast cancer

  2025cites this paper
• Breast cancer histopathology, classification and clinical management: Current perspectives

  2024cites this paper
• MALAT1-dependent hsa_circ_0076611 regulates translation rate in triple-negative breast cancer

  2022cites this paper
• ID1 and ID4 Are Biomarkers of Tumor Aggressiveness and Poor Outcome in Immunophenotypes of Breast Cancer

  2021cites this paper
• Cancer-Testis Antigens in Triple-Negative Breast Cancer: Role and Potential Utility in Clinical Practice

  2021cites this paper
• BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer

  2020cites this paper
• Prognostic effects of the expression of inhibitor of DNA-binding family members on patients with lung adenocarcinoma

  2020cites this paper
• Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer

  2020cites this paper
• ID4 Promotes Breast Cancer Chemotherapy Resistance via CBF1-MRP1 Pathway

  2020cites this paper
• Paracrine Signaling from Breast Cancer Cells Causes Activation of ID4 Expression in Tumor-Associated Macrophages

  2020cites this paper
• Characteristics, behaviour and role of biomarkers in metastatic triple-negative breast cancer

  2019cites this paper
• BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers.

  2018cites this paper
• A novel role for the HLH protein Inhibitor of Differentiation 4 (ID4) in the DNA damage response in basal-like breast cancer

  2018cites this paper
• Prognostic values of the inhibitor of DNA-binding family members in breast cancer

  2018cites this paper
• Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages

  2018cites this paper
• The mutant p53‐ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1

  2017cites this paper
• Title : The mutant p 53-ID 4 complex controls VEGFA isoforms production by recruiting lncRNA MALAT 1

  2017cites this paper
• ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer.

  2016cites this paper
• ID 4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA 1 function in basal-like breast cancer

  2016cites this paper
• Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer

  2016cites this paper
• Che-1 gene silencing induces osteosarcoma cell apoptosis by inhibiting mutant p53 expression.

  2016cites this paper